<description>&lt;p&gt;&lt;span style="font-weight: 400;"&gt;Dans cette 72&lt;/span&gt;&lt;span style="font-weight: 400;"&gt;e&lt;/span&gt;&lt;span style="font-weight: 400;"&gt; baladodiffusion, les Drs Alexandre Mutchmore et Dusanka Grbic discutent du sémaglutide comme traitement de la stéatohépatite liée à une dysfonction métabolique, en plus de réviser la littérature médicale de mai et juin 2025.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Quiz clinique (3 min 33), présentation principale (4 min 12), critique (29 min 25), retour sur le cas clinique (36 min 29), autres articles (39 min 00), réponse au quiz clinique (43 min 39)&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h1&gt;&lt;b&gt;Référence principale :&lt;/b&gt;&lt;/h1&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-99. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40305708/"&gt;&lt;span style="font-weight: 400;"&gt;40305708&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h2&gt;&lt;b&gt;Articles associés : &lt;/b&gt;&lt;/h2&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Simon TG. Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2160-1. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40466070/"&gt;&lt;span style="font-weight: 400;"&gt;40466070&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/38324483/"&gt;&lt;span style="font-weight: 400;"&gt;38324483&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/36727674/"&gt;&lt;span style="font-weight: 400;"&gt;36727674&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/38851997/"&gt;&lt;span style="font-weight: 400;"&gt;38851997&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761-1778. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/39488409/"&gt;&lt;span style="font-weight: 400;"&gt;39488409&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/38847460/"&gt;&lt;span style="font-weight: 400;"&gt;38847460&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/38856224/"&gt;&lt;span style="font-weight: 400;"&gt;38856224&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40467095/"&gt;&lt;span style="font-weight: 400;"&gt;40467095&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h2&gt;&lt;b&gt;Autres articles d’intérêt récent : &lt;/b&gt;&lt;/h2&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987-2000. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40167274/"&gt;&lt;span style="font-weight: 400;"&gt;40167274&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-93. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40169145/"&gt;&lt;span style="font-weight: 400;"&gt;40169145&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025;392(20):2013-24. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40174237/"&gt;&lt;span style="font-weight: 400;"&gt;40174237&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025;392(18):1813-23. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40267417/"&gt;&lt;span style="font-weight: 400;"&gt;40267417&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Garrison SR, Bakal JA, Kolber MR, Korownyk CS, Green LA, Kirkwood JEM, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025;333(23):2061-72. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40354045/"&gt;&lt;span style="font-weight: 400;"&gt;40354045&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Herrmann JJ, Brunner-La Rocca HP, Baltussen L, Beckers-Wesche F, Bekkers S, Bellersen L, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med. 2025;31(6):2062-8. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40159556/"&gt;&lt;span style="font-weight: 400;"&gt;40159556&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193-202. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40387033/"&gt;&lt;span style="font-weight: 400;"&gt;40387033&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2203-14. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40388329/"&gt;&lt;span style="font-weight: 400;"&gt;40388329&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025;333(23):2073-82. PubMed PMID: &lt;/span&gt;&lt;a href="about:blank"&gt;&lt;span style="font-weight: 400;"&gt;40366680&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h2&gt;&lt;b&gt;Guides de pratique : &lt;/b&gt;&lt;/h2&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E64. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40419299/"&gt;&lt;span style="font-weight: 400;"&gt;40419299&lt;/span&gt;&lt;/a&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Tobe SW, Bajaj HS, Tangri N, Jain R, Pham T, Beaudin V, et al. Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline. Can J Diabetes. 2025;49(2):73-86. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40382193/"&gt;&lt;span style="font-weight: 400;"&gt;40382193&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Mir H, Eisenberg MJ, Benowitz NL, Cowley E, Heshmati J, Jha P, et al. Canadian Cardiovascular Society Clinical Practice Update on Contemporary Approaches to Smoking Cessation. Can J Cardiol. 2025;41(5):797-812. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40340054/"&gt;&lt;span style="font-weight: 400;"&gt;40340054&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Osiowy C, Alvarez F, Coffin CS, Cooper CL, Fung SK, Ko HH, et al. The management of chronic hepatitis B: 2025 Guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Canadian Liver Journal. 2025;8(2):368-401. &lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Rao SV, O&amp;rsquo;Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-237. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40013746/"&gt;&lt;span style="font-weight: 400;"&gt;40013746&lt;/span&gt;&lt;/a&gt;&lt;span style="font-weight: 400;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120(6):1187-224. &lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn&amp;rsquo;s Disease in Adults. Am J Gastroenterol. 2025;120(6):1225-64.&lt;/span&gt;&lt;/p&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h2&gt;&lt;b&gt;Référence du quiz clinique :&lt;/b&gt;&lt;/h2&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;p&gt;&lt;span style="font-weight: 400;"&gt;Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E64. PubMed PMID: &lt;/span&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/40419299/"&gt;&lt;span style="font-weight: 400;"&gt;40419299&lt;/span&gt;&lt;/a&gt;&lt;/p&gt; </description>

BaladoCritique - club de lecture médical

Dr Luc Lanthier et collaborateurs

BC 072 – Sémaglutide dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude ESSENCE)

JUL 6, 202546 MIN
BaladoCritique - club de lecture médical

BC 072 – Sémaglutide dans le traitement de la stéatohépatite liée à une dysfonction métabolique (étude ESSENCE)

JUL 6, 202546 MIN

Description

<p><span style="font-weight: 400;">Dans cette 72</span><span style="font-weight: 400;">e</span><span style="font-weight: 400;"> baladodiffusion, les Drs Alexandre Mutchmore et Dusanka Grbic discutent du sémaglutide comme traitement de la stéatohépatite liée à une dysfonction métabolique, en plus de réviser la littérature médicale de mai et juin 2025.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Quiz clinique (3 min 33), présentation principale (4 min 12), critique (29 min 25), retour sur le cas clinique (36 min 29), autres articles (39 min 00), réponse au quiz clinique (43 min 39)</span></p> <p>&nbsp;</p> <h1><b>Référence principale :</b></h1> <p>&nbsp;</p> <p><span style="font-weight: 400;">Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-99. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40305708/"><span style="font-weight: 400;">40305708</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Articles associés : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Simon TG. Semaglutide for Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2160-1. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40466070/"><span style="font-weight: 400;">40466070</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/38324483/"><span style="font-weight: 400;">38324483</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/36727674/"><span style="font-weight: 400;">36727674</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/38851997/"><span style="font-weight: 400;">38851997</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761-1778. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/39488409/"><span style="font-weight: 400;">39488409</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al 1404-0043 Trial Investigators. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/38847460/"><span style="font-weight: 400;">38847460</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/38856224/"><span style="font-weight: 400;">38856224</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Lin J, Huang Y, Xu B, Gu X, Huang J, Sun J, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40467095/"><span style="font-weight: 400;">40467095</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Autres articles d’intérêt récent : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025;392(20):1987-2000. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40167274/"><span style="font-weight: 400;">40167274</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-93. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40169145/"><span style="font-weight: 400;">40169145</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. N Engl J Med. 2025;392(20):2013-24. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40174237/"><span style="font-weight: 400;">40174237</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025;392(18):1813-23. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40267417/"><span style="font-weight: 400;">40267417</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Garrison SR, Bakal JA, Kolber MR, Korownyk CS, Green LA, Kirkwood JEM, et al. Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial. JAMA. 2025;333(23):2061-72. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40354045/"><span style="font-weight: 400;">40354045</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Herrmann JJ, Brunner-La Rocca HP, Baltussen L, Beckers-Wesche F, Bekkers S, Bellersen L, et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med. 2025;31(6):2062-8. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40159556/"><span style="font-weight: 400;">40159556</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2193-202. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40387033/"><span style="font-weight: 400;">40387033</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392(22):2203-14. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40388329/"><span style="font-weight: 400;">40388329</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025;333(23):2073-82. PubMed PMID: </span><a href="about:blank"><span style="font-weight: 400;">40366680</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <h2><b>Guides de pratique : </b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E64. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40419299/"><span style="font-weight: 400;">40419299</span></a></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Tobe SW, Bajaj HS, Tangri N, Jain R, Pham T, Beaudin V, et al. Chronic Kidney Disease in Diabetes: A Clinical Practice Guideline. Can J Diabetes. 2025;49(2):73-86. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40382193/"><span style="font-weight: 400;">40382193</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Mir H, Eisenberg MJ, Benowitz NL, Cowley E, Heshmati J, Jha P, et al. Canadian Cardiovascular Society Clinical Practice Update on Contemporary Approaches to Smoking Cessation. Can J Cardiol. 2025;41(5):797-812. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40340054/"><span style="font-weight: 400;">40340054</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Osiowy C, Alvarez F, Coffin CS, Cooper CL, Fung SK, Ko HH, et al. The management of chronic hepatitis B: 2025 Guidelines update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada. Canadian Liver Journal. 2025;8(2):368-401. </span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Rao SV, O&rsquo;Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander JH, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-237. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40013746/"><span style="font-weight: 400;">40013746</span></a><span style="font-weight: 400;">.</span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025;120(6):1187-224. </span></p> <p>&nbsp;</p> <p><span style="font-weight: 400;">Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn&rsquo;s Disease in Adults. Am J Gastroenterol. 2025;120(6):1225-64.</span></p> <p>&nbsp;</p> <h2><b>Référence du quiz clinique :</b></h2> <p>&nbsp;</p> <p><span style="font-weight: 400;">Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197(20):E549-E64. PubMed PMID: </span><a href="https://pubmed.ncbi.nlm.nih.gov/40419299/"><span style="font-weight: 400;">40419299</span></a></p>